Previous 10 | Next 10 |
AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...
- Longest available outcomes data with LUPKYNIS will be presented virtually during American College of Rheumatology (ACR) Convergence 2021; final results expected by the end of 2021 – - Updated interim analysis shows sustained safety and tolerability of LUPKYNIS compare...
Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 1.3% after GlaxoSmithKline (NYSE:GSK) denied a Mail report from Sunday that the company was considering a bid for the company. A GSK spokeswoman told Reuters the report isn't true. Aurinia (AUPH) gained last week after speculation that seve...
Aurinia Pharmaceuticals (NASDAQ:AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers, according to Cantor Fitgzerald. Aurinia rose 1.5%. Other companies that could be interested include Amgen (NASDAQ:AMGN), AbbVie (NYSE:ABBV), J...
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded today at a new 52-week high of $32.65. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 4.4 million shares. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides produc...
Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 4.4% after speculation that several other pharma companies may be looking at the company. GlaxoSmithKline (NYSE:GSK), Roche (OTCQX:RHHBY) and Otsuka Pharmaceuticals (OTCPK:OTSKF) are speculated are speculated to reviewing a poten...
Oppenheimer has downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from outperform to perform following a report that the company may be acquired by Bristol-Myers Squibb (NYSE:BMY). In addition, the firm says that the current share price reflects appropriate valuation. Oppenheimer has a $32 pri...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open. Aurinia’s management team will also host a conference call at 8:30 a.m....
Top Biotech Stocks To Consider Buying [Or Selling] This Week Depending on your investment appetite, the stock market offers various types of opportunities. Biotech stocks have a reputation for being a high-risk, high-reward kind of investment. Over the past two years, countless ...
Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune diseas...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...